Claes Tomas Post
Directeur/Bestuurslid bij Oblique Therapeutics AB
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Per Anders Wärn | M | 63 |
Stockholms Affärsänglar Management AB
 Stockholms Affärsänglar Management AB Investment ManagersFinance Stockholms Affärsänglar Management AB (STOAF) is a venture capital firm founded in 2008 by Ted Ingemar Elvhage, Klaus Olle Alfred Gottwald and Åke Lennart Ohlsson. The firm is headquartered In Stockholm, Sweden.
STOAF III Venture Partners AB
| 6 jaar |
| Klaus Olle Alfred Gottwald | M | 73 |
Stockholms Affärsänglar Management AB
Stockholms Affärsänglar Management AB Investment ManagersFinance Stockholms Affärsänglar Management AB (STOAF) is a venture capital firm founded in 2008 by Ted Ingemar Elvhage, Klaus Olle Alfred Gottwald and Åke Lennart Ohlsson. The firm is headquartered In Stockholm, Sweden. | 16 jaar |
| Hans-Peter Albert Ostler | M | 53 |
Oblique Therapeutics AB
 Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Mats Bo Johan Nilsson Bernitz | M | 54 |
University of Uppsala
| 25 jaar |
| Magnus Eriksson | M | - |
Stockholms Affärsänglar Management AB
Stockholms Affärsänglar Management AB Investment ManagersFinance Stockholms Affärsänglar Management AB (STOAF) is a venture capital firm founded in 2008 by Ted Ingemar Elvhage, Klaus Olle Alfred Gottwald and Åke Lennart Ohlsson. The firm is headquartered In Stockholm, Sweden. | 5 jaar |
| Rajeev Ahuja | M | - |
University of Uppsala
| - |
| Henrik Didner | M | 66 |
Gradientech AB
 Gradientech AB BiotechnologyHealth Technology Gradientech AB operates as biotech and diagnostics company. It develops and provides ultra-rapid antibiotic susceptibility testing products. The company's products include QuickMic, CellDirector and Tracking Tool PRO. Gradientech was founded by Sara Ulrika Thorslund and Johan Kreuger in 2009 and is headquartered in Uppsala, Sweden. | 6 jaar |
| Anders R. Hallberg | M | 79 |
University of Uppsala
| 6 jaar |
| Tor Leif Olof Kihlberg | M | 49 |
Almi Invest AB
 Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | 11 jaar |
| Niklas Dahl | M | - |
University of Uppsala
| 24 jaar |
| Sverker Ljunghall | M | - |
University of Uppsala
| - |
| Christer Malmberg | M | 40 |
Gradientech AB
Gradientech AB BiotechnologyHealth Technology Gradientech AB operates as biotech and diagnostics company. It develops and provides ultra-rapid antibiotic susceptibility testing products. The company's products include QuickMic, CellDirector and Tracking Tool PRO. Gradientech was founded by Sara Ulrika Thorslund and Johan Kreuger in 2009 and is headquartered in Uppsala, Sweden. | 10 jaar |
| Håkan Gunnar Engqvist | M | 52 |
University of Uppsala
| - |
| Per Åke Antonsson | M | 64 |
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | 11 jaar |
| Marcus Berglund | M | 43 |
Gradientech AB
Gradientech AB BiotechnologyHealth Technology Gradientech AB operates as biotech and diagnostics company. It develops and provides ultra-rapid antibiotic susceptibility testing products. The company's products include QuickMic, CellDirector and Tracking Tool PRO. Gradientech was founded by Sara Ulrika Thorslund and Johan Kreuger in 2009 and is headquartered in Uppsala, Sweden. | 7 jaar |
| Carl-Hendrik Heldin | M | 72 |
University of Uppsala
| 32 jaar |
| Margareta Elisabeth Björk | M | 63 |
University of Uppsala
| - |
| Magnus Essand | M | 60 |
University of Uppsala
| 15 jaar |
| Angelica Loskog | M | 51 |
University of Uppsala
| - |
| Johan Lindh | M | - |
University of Uppsala
| 10 jaar |
| Ulf Bertil Olof Göransson | M | 54 |
University of Uppsala
| - |
| Lars Thomander | M | 77 |
University of Uppsala
| - |
| Bengt Westermark | M | 79 |
University of Uppsala
| 38 jaar |
| Marie-Louise Fjaellskog | M | 59 |
University of Uppsala
| 16 jaar |
| Gunnar Telhammar | M | 63 | 11 jaar | |
| Ulf Green | M | - |
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | 10 jaar |
| Anne Ramberg | F | - |
University of Uppsala
| - |
| Christer Nordstedt | M | 62 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 2 jaar |
| Per Matsson | M | 70 |
University of Uppsala
| - |
| Hilpi Rautelin | M | 63 |
University of Uppsala
| 16 jaar |
| Eva Ursula Hultqvist Bengtsson | M | 64 |
University of Uppsala
| - |
| Peter von Ehrenheim | M | 69 |
University of Uppsala
| - |
| Per Gunningberg | M | 71 |
University of Uppsala
| - |
| Ingemar Kihlström | M | 72 |
University of Uppsala
| - |
| Gudrun Anstrén | F | 69 |
Apotekarsocieteten
| - |
| Daniel Johnsson | M | 56 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Henrik Larsson | M | - |
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | 10 jaar |
| Johan Olof Kämpe | M | 68 |
University of Uppsala
| 25 jaar |
| Mathias Hallberg | M | 53 |
University of Uppsala
| - |
| Rolf Larsson | M | - |
University of Uppsala
| - |
| Karl Johan Anders Wall | M | 60 |
University of Uppsala
| - |
| Lars Ture Pettersson | M | 70 |
University of Uppsala
| - |
| Rolf Larsson | M | - |
University of Uppsala
| - |
| Gustav Ingemar Kihlström | M | 71 |
University of Uppsala
| - |
| Jan Thorell | M | - |
University of Uppsala
| - |
| Marek Kwiatkowski | M | 74 |
University of Uppsala
| - |
| Alf Gunnar Martin Nicklasson | M | 69 |
University of Uppsala
| - |
| Lilian Birgitta Wikström | M | 63 |
Karolinska Institutet Innovations AB
 Karolinska Institutet Innovations AB Financial ConglomeratesFinance Karolinska Institutet Innovations AB enables education, professional networking, funding, expertise in entrepreneurship and business development, and incubation opportunities for life science projects and companies. The company was founded in 1996 and is headquartered in Solna, Sweden. | 14 jaar |
| Jonas Göran Ekblom | M | 59 |
University of Uppsala
| - |
| Bengt Gerdin | M | 77 |
University of Uppsala
| 30 jaar |
| Marcus Skärbäck | M | 52 |
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | 11 jaar |
| Margot Gunilla Fransson | M | 64 |
University of Uppsala
| - |
| Nils Martin Malmsten | M | - |
University of Uppsala
| - |
| Ernst Åke Bertil Karlmark | M | 86 |
University of Uppsala
| - |
| Ingemar Lundström | M | 83 |
University of Linköping
 University of Linköping Other Consumer ServicesConsumer Services Linköping University Hospital provides healthcare services. | 46 jaar |
| Jonas Rastad | M | 74 |
University of Uppsala
| - |
| Lars Harald Baltzer | M | 73 |
University of Uppsala
| - |
| Ulla Helena Danielson | M | - |
University of Uppsala
| 22 jaar |
| Johan Stenberg | M | - |
University of Uppsala
| - |
| Karin Inga Margareta Josefsson | F | 75 |
University of Linköping
University of Linköping Other Consumer ServicesConsumer Services Linköping University Hospital provides healthcare services. | 14 jaar |
| Anders Wilhelmson | M | - |
University of Uppsala
| - |
| Andreas Waber | M | - |
University of Uppsala
| - |
| Knut Lars Carl Wiklund | M | 81 |
University of Uppsala
| - |
| Lars Bohlin | M | 76 |
University of Uppsala
| - |
| Bo Walter Wennström | M | 70 |
University of Uppsala
| - |
| Per Christer Folke Lundberg | M | 81 |
University of Uppsala
| - |
| Ingrid Westin Wallinder | F | 67 |
University of Uppsala
| - |
| Lennart Erik Jonas Sjögren | M | 58 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Marianne Dicander Alexandersson | F | 65 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Thomas Areschoug | M | 52 | 7 jaar | |
| Mats Lindskog | M | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Åke Ohlsson | M | 82 |
Stockholms Affärsänglar Management AB
Stockholms Affärsänglar Management AB Investment ManagersFinance Stockholms Affärsänglar Management AB (STOAF) is a venture capital firm founded in 2008 by Ted Ingemar Elvhage, Klaus Olle Alfred Gottwald and Åke Lennart Ohlsson. The firm is headquartered In Stockholm, Sweden. | 12 jaar |
| Sven Kili | M | 57 | 8 jaar | |
| Gunilla Lundmark | F | 61 |
University of Uppsala
| 2 jaar |
| Olof Löfving | M | - |
University of Uppsala
| 5 jaar |
| Arno Niazi | M | - |
University of Uppsala
| 4 jaar |
| Charbel Altunkaynak | M | - |
University of Uppsala
| 5 jaar |
| Iliam Barkino | M | - |
University of Uppsala
| 5 jaar |
| Fredrik Dahl | M | - |
University of Uppsala
| - |
| Andreas Ueno-Olausson | M | - |
University of Uppsala
| 6 jaar |
| Jamal Abisourour | M | - |
University of Uppsala
| 1 jaar |
| Alex Basu | M | - |
University of Uppsala
| 9 jaar |
| Joachim Carlsson | M | - |
University of Uppsala
| 4 jaar |
| Christer Thordson | M | 66 |
University of Uppsala
| 4 jaar |
| Stefan Knutsson | M | - |
University of Uppsala
| 6 jaar |
| Anders Johansson | M | 48 |
University of Uppsala
| 3 jaar |
| Björn Henriksson | M | - |
University of Uppsala
| 13 jaar |
| Ted Ingemar Elvhage | M | 56 |
Gradientech AB
Gradientech AB BiotechnologyHealth Technology Gradientech AB operates as biotech and diagnostics company. It develops and provides ultra-rapid antibiotic susceptibility testing products. The company's products include QuickMic, CellDirector and Tracking Tool PRO. Gradientech was founded by Sara Ulrika Thorslund and Johan Kreuger in 2009 and is headquartered in Uppsala, Sweden. | 9 jaar |
| Charlotta Göransson | M | 52 |
University of Uppsala
| 5 jaar |
| Eric Gunnar Daniel Persson | M | 52 |
University of Uppsala
| 4 jaar |
| Bengt Gustaf Gustavsson | M | 77 |
University of Uppsala
| 8 jaar |
| Paola Longati | M | - |
Melacure Therapeutics AB
 Melacure Therapeutics AB Pharmaceuticals: MajorHealth Technology Melacure Therapeutics AB develops and manufactures pharmaceutical products. Its products are used for treatment of obesity, irritable bowel syndrome, inflammation, and sexual dysfunction. The company was founded in 1998 and is located in Uppsala, Sweden.
University of Uppsala
| 5 jaar |
| Jonas Sven Peter Jarvius | M | 53 |
University of Uppsala
| 5 jaar |
| Mats Gullberg | M | 53 |
University of Uppsala
| 5 jaar |
| Lars Stolt | M | - |
University of Uppsala
| 8 jaar |
| Sven Håkan Björklund | M | 68 |
Astra Pain Control AB
Astra Draco AB
| 7 jaar |
| Leif Peter Karlsten | M | 67 |
University of Linköping
University of Linköping Other Consumer ServicesConsumer Services Linköping University Hospital provides healthcare services.
University of Uppsala
| 7 jaar |
| Carl M. Svernlöv | M | - |
University of Uppsala
| 2 jaar |
| Henrik Paulsson | M | - |
University of Uppsala
| 2 jaar |
| Daniel Ketema | M | - |
University of Uppsala
| 6 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Zweden | 100 | 100.00% |
| Italië | 0 | -.--% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Claes Tomas Post
- Persoonlijk netwerk